Macular Degeneration Clinical Trial
— FLAPOfficial title:
Characterization of Multiple Factors in Training and Plasticity in Central Vision Loss: Macular Degeneration
A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the NIMH RDOC framework and studies in an aging population are consistent with the mission of the NIA.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - Aged 18-89 - Severely impaired vision in both eyes (20/100 or worse) - diagnosis of Macular Degeneration by an Ophthalmologist - Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (MAIA) - Medical record review indicating this level of disease severity has been present for at least 2 years - Reside within 50 miles of study site Exclusion Criteria: - Pacemaker or any ferromagnetic metal implanted in their body - Metal of any type implanted in their head (limited dental work is acceptable) - Claustrophobia - Being hearing-impaired - Weight over 300 pounds - Maximum body girth over 60 inches - Previous serious head injury - Presence of hallucinations or delusions - Excessive old, or colorful tattoos, especially near the head - Pregnancy - Braces/permanent retainer |
Country | Name | City | State |
---|---|---|---|
United States | UAB | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | University of California, Riverside |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from Baseline Acuity after Completion of Training at approximately 7 weeks | Acuity threshold from the Landolt C task. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Contrast Sensitivity after Completion of Training at approximately 7 weeks | Threshold value from contrast sensitivity task. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Minimal print size from the MNREAD task after Completion of Training at approximately 7 weeks | Minimal print size from the MNREAD task | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Precision of Reconstructed Representation of Stimulus Orientation after Completion of Training at approximately 7 weeks | Precision of reconstructed representation of stimulus orientation (quantified with FWHM) | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Population receptive field size in V1, V2 and V3 representations of URL and PRL after Completion of Training at approximately 7 weeks | Population receptive field size in V1, V2 and V3 representations of URL and PRL (quantified as PRF sigma in the swath of cortex associated with that retinal location). | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Cortical thickness in V1, V2 and V3 representations of the PRL and URL after Completion of Training at approximately 7 weeks | Cortical thickness in V1, V2 and V3 representations of the PRL and URL (quantified as mm of cortical thickness) | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Orientation jitter threshold in the contour integration task at PRL or URL after Completion of Training at approximately 7 weeks | Orientation jitter threshold in the contour integration task (quantified as threshold average jitter) at PRL or URL. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Crowding Threshold after Completion of Training at approximately 7 weeks | In the contour integration task stimuli are untrained contours of alphanumeric characters made of Gabor elements. This test allows us to estimate how the magnitude of crowding may change at the PRL compared to the non-PRL. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Decoding classification accuracy for an attended character after Completion of Training at approximately 7 weeks | Decoding classification accuracy for an attended character, based on decoding from MRI data within VWFA and LOC regions of interest. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Strength of background connectivity between areas with larger receptive fields (V4) to the smaller receptive fields contributing information to that area. after Completion of Training at approximately 7 weeks | This is measured as functional connectivity (z-transformed Pearson's r) between voxels in V1 to voxels in V4 in that represent the same portion of retinotopically mapped space. Measured in portions of cortex representing PRL and URL. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Sustained Attention after Completion of Training at approximately 7 weeks | Reaction time of detection of orientation of Landolt Cs presented in an RSVP stream at the beginning of each trial. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Endogenous Attention after Completion of Training at approximately 7 weeks | Endogenous attention: reaction time when switching between locations due to an endogenous cue on valid vs nonvalid trials. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Exogenous Attention after Completion of Training at approximately 7 weeks | Exogenous attention: reaction time when switching between locations due to an exogenous cue on valid vs. nonvalid trials. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Saccadic Re-referencing after Completion of Training at approximately 7 weeks | Saccadic Re-referencing: number of first fixations that do not cover the target location with the scotoma. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Decoding classification accuracy for decoding the locus of spatial attention (PRL or URL), regardless of stimulus type after Completion of Training at approximately 7 weeks | Decoding classification accuracy for decoding the locus of spatial attention (PRL or URL), regardless of stimulus type. This will be examined in frontal (FEF), parietal (SPL/IPS) and higher order visual (LOC) regions. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Top-down modulation of visual areas after Completion of Training at approximately 7 weeks | Top-down modulation of visual areas: background connectivity between frontoparietal control regions (FEF, SPL/IPS) and visual areas ( V1, V2, V3). | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Reading speed in the MNREAD task after Completion of Training at approximately 7 weeks | Reading speed in the MNREAD task (words per minute). | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Other | Change from Baseline Completion time in the trail making task after Completion of Training at approximately 7 weeks | Completion time in the trail making task | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Primary | Change from Baseline Radial Bias from the Crowding Task after completion of Training at approximately 7 weeks | The ratio of the crowding threshold along the axis connected to the fovea vs. along the orthogonal axis. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Primary | Change from Baseline Saccadic Precision after Completion of Training at approximately 7 weeks | Consistency across trials in placement of the first saccade calculated by the distribution across trials (bivariate contour ellipse area) of the landing point of the first fixation of each trial. | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average | |
Primary | Change from Baseline Fixation Stability after Completion of Training at approximately 7 weeks | Normalizing fixations in the PRL to the first fixation to that region and calculating the distribution of all fixation locations in this normalized space (measured as a bivariate contour ellipse area). | Baseline and Within 3 weeks of training completion, training is complete 7 weeks from baseline on average |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |